|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.01.26 - 01:12
|
UK business confidence weakened and hiring fell at end of 2025, surveys find (The Guardian)
|
|
|
Rising costs and economic uncertainty take toll, in contrast to Keir Starmer saying Britain will start to feel richerUK business confidence weakened sharply at the end of 2025 and hiring fell amid rising costs and uncertainty about the economic outlook, according to key business surveys.Contrasting with the prime minister's optimistic new year message that the country was about to start feeling richer again, the jobs market weakened, with full-time and temporary appointments falling in December, according to a study by the accountants KPMG and the Recruitment and Employment Confederation (REC). Continue reading......
|
|
|
12.01.26 - 00:36
|
Which stocks will Hang Seng Bank shareholders consider with their US$14 billion windfall? (SCMP)
|
|
|
High-dividend yielding Hong Kong and mainland banking stocks are likely to attract investors looking to park some of the HK$106.16 billion (US$13.6 billion) windfall from the Hang Seng Bank privatisation deal, according to analysts.
They tipped Bank of China (Hong Kong) and HSBC to be among the biggest beneficiaries these investors seek as dividend-paying replacements.
About 15,000 Hang Seng Bank shareholders are expected to receive their payout cheques by February 4 in exchange for their......
|
|
|
11.01.26 - 23:18
|
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo (GlobeNewswire EN)
|
|
|
NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-'408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-'408 trials during 2026....
|
|
|
11.01.26 - 23:03
|
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo (GlobeNewswire EN)
|
|
|
PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-'408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-'408 trials during 2026....
|
|
|
|
|
|
|
|
|
|
|
|
|
11.01.26 - 16:54
|
Draft ′Farage clause′ would ensure EU not out of pocket if Reform UK wins election (The Guardian)
|
|
|
Termination clause is a stark reminder of EU's colossal fund to help member states cope with BrexitThe EU is reportedly demanding guarantees the UK will compensate the bloc if a future government reneges on the Brexit “reset” agreement Keir Starmer is currently negotiating.The termination clause is a stark reminder of the painful and costly divorce in which the EU set up a colossal €5.4bn (£4.7bn) fund to help its own member states cope with the disruption caused by the UK's exit in 2020. Continue reading......
|
|
|
|
Alle News zu Großbritannien 10117.988 -0.21% (FTSE 100 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
